Zimmer Biomet (ZBH) Set to Announce Earnings on Thursday

Zimmer Biomet (NYSE:ZBHGet Free Report) will release its earnings data before the market opens on Thursday, February 8th. Analysts expect Zimmer Biomet to post earnings of $2.15 per share for the quarter. Persons that are interested in participating in the company’s earnings conference call can do so using this link.

Zimmer Biomet (NYSE:ZBHGet Free Report) last issued its quarterly earnings data on Tuesday, November 7th. The medical equipment provider reported $1.65 earnings per share for the quarter, beating analysts’ consensus estimates of $1.59 by $0.06. Zimmer Biomet had a return on equity of 12.41% and a net margin of 6.52%. The company had revenue of $1.75 billion for the quarter, compared to the consensus estimate of $1.75 billion. During the same quarter last year, the company earned $1.58 earnings per share. The firm’s revenue for the quarter was up 5.0% compared to the same quarter last year. On average, analysts expect Zimmer Biomet to post $8 EPS for the current fiscal year and $8 EPS for the next fiscal year.

Zimmer Biomet Price Performance

Shares of ZBH stock opened at $127.60 on Wednesday. Zimmer Biomet has a 1-year low of $102.00 and a 1-year high of $149.25. The stock’s 50-day moving average is $120.88 and its 200 day moving average is $117.70. The company has a market cap of $26.67 billion, a P/E ratio of 56.46, a PEG ratio of 2.32 and a beta of 1.03. The company has a debt-to-equity ratio of 0.41, a current ratio of 2.11 and a quick ratio of 0.99.

Zimmer Biomet Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Wednesday, January 31st. Investors of record on Wednesday, December 27th were given a dividend of $0.24 per share. This represents a $0.96 dividend on an annualized basis and a yield of 0.75%. The ex-dividend date was Tuesday, December 26th. Zimmer Biomet’s payout ratio is currently 42.48%.

Hedge Funds Weigh In On Zimmer Biomet

A number of institutional investors and hedge funds have recently added to or reduced their stakes in ZBH. Clear Street Markets LLC purchased a new stake in Zimmer Biomet in the fourth quarter valued at $27,000. Lazard Asset Management LLC raised its position in Zimmer Biomet by 70.5% in the third quarter. Lazard Asset Management LLC now owns 283 shares of the medical equipment provider’s stock valued at $31,000 after purchasing an additional 117 shares during the period. Dark Forest Capital Management LP purchased a new stake in Zimmer Biomet in the first quarter valued at $35,000. KB Financial Partners LLC purchased a new stake in Zimmer Biomet in the first quarter valued at $49,000. Finally, Sunbelt Securities Inc. purchased a new stake in Zimmer Biomet in the first quarter valued at $90,000. Institutional investors and hedge funds own 87.48% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts have weighed in on ZBH shares. JPMorgan Chase & Co. lowered their price target on Zimmer Biomet from $146.00 to $115.00 and set a “neutral” rating for the company in a report on Wednesday, November 8th. Roth Mkm assumed coverage on Zimmer Biomet in a research note on Friday, October 20th. They issued a “neutral” rating and a $120.00 price objective for the company. Raymond James raised their price objective on Zimmer Biomet from $133.00 to $137.00 and gave the stock an “outperform” rating in a research note on Wednesday, January 3rd. Morgan Stanley raised their price objective on Zimmer Biomet from $120.00 to $125.00 and gave the stock an “equal weight” rating in a research note on Monday, December 4th. Finally, JMP Securities reduced their price objective on Zimmer Biomet from $160.00 to $140.00 and set a “market outperform” rating for the company in a research note on Monday, November 13th. Two equities research analysts have rated the stock with a sell rating, eight have given a hold rating and seven have issued a buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $137.47.

Check Out Our Latest Report on Zimmer Biomet

Zimmer Biomet Company Profile

(Get Free Report)

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company designs, manufactures, and markets orthopaedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.

Featured Stories

Earnings History for Zimmer Biomet (NYSE:ZBH)

Receive News & Ratings for Zimmer Biomet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet and related companies with MarketBeat.com's FREE daily email newsletter.